Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 441 to 450 of 1106 total matches.

Altretamine For Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991  (Issue 850)
concern about using these drugs together. Limited data suggest, however, that altretamine adds little ...
Altretamine (Hexalen - US Bioscience; Hexastat - Rh ne-Poulenc in Canada), formerly known only by its chemical name, hexamethylmelamine, was recently approved by the US Food and Drug Administration as a single agent for palliative oral treatment of persistent or recurrent ovarian cancer.
Med Lett Drugs Ther. 1991 Aug 9;33(850):76-7 |  Show IntroductionHide Introduction

Topical Drugs For Vaginal Candidiasis

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 1991  (Issue 851)
may be embryotoxic in rats or mice. CONCLUSION — Available data suggest that all approved regimens of topical ...
Many drugs, mostly imidazole derivatives, are marketed in the USA for topical treatment of vulvovaginal candidiasis, and a few are now available without a prescription.
Med Lett Drugs Ther. 1991 Aug 23;33(851):81 |  Show IntroductionHide Introduction

Intranasal Triamcinolone For Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 1991  (Issue 859)
is effective for relief of symptoms of allergic rhinitis. Published data are insufficient to determine how ...
An intranasal formulation of the corticosteroid triamcinolone (Nasacort - Rh ne- Poulenc Rorer) was recently approved by the US Food and Drug Administration for once-daily treatment of seasonal and perennial allergic rhinitis.
Med Lett Drugs Ther. 1991 Dec 13;33(859):116-7 |  Show IntroductionHide Introduction

Podofilox For Genital Warts

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 1991  (Issue 859)
the pharmacist $48, according to Average Wholesale Price listings in First DataBank PriceAlert, November 15 ...
Podofilox 0.5% solution (Condylox - Oclassen) was recently approved by the US Food and Drug Administration for treatment of (condylomata acuminata). The drug requires a prescription, but is labeled for application by the patient. Similar topical solutions previously available for this indication are approved only for application by the physician.
Med Lett Drugs Ther. 1991 Dec 13;33(859):117-8 |  Show IntroductionHide Introduction

Quinapril for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Mar 20, 1992  (Issue 866)
with the lowest usual dosage, according to Average Wholesale Prices listed in First DataBank PriceAlert, February ...
Quinapril (Accupril - Parke-Davis), an angiotensin-converting enzyme (ACE) inhibitor, has been approved by the US Food and Drug Administration (FDA) for treatment of hypertension. ACE inhibitors are now widely used for this indication (Medical Letter, 33:33, 1991).
Med Lett Drugs Ther. 1992 Mar 20;34(866):27-8 |  Show IntroductionHide Introduction

Atovaquone for Pneumocystis Carinii Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Apr 02, 1993  (Issue 893)
, 8:We48, 1992, abs.) Unpublished data indicate that atovaquone is also less effective than IV ...
Atovaquone (Mepron - Burroughs Wellcome), a hydroxynaphthoquinone, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients who cannot tolerate trimethoprim-sulfamethoxazole (Septra, Bactrim, and others). PCP is a common opportunistic infection and frequent cause of death in patients with AIDS.
Med Lett Drugs Ther. 1993 Apr 2;35(893):28-9 |  Show IntroductionHide Introduction

Ketorolac for Seasonal Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Sep 17, 1993  (Issue 905)
conjunctivitis, but supporting data are limited and unimpressive, and it is expensive. Comparisons ...
Ketorolac (kee' toe role ak) tromethamine 0.5%, a nonsteroidal anti-inflammatory drug (NSAID) previously available for parenteral and oral administration (Toradol - Medical Letter, 32:79, 1990), has now been approved for ophthalmic use (Acular - Allergan, Fisons) to relieve itching in seasonal allergic conjunctivitis. NSAIDs decrease prostaglandin concentrations in the eye, which theoretically might contribute to a decrease in itching. Several other NSAIDs are available for ophthalmic use in the USA, but none is marketed for this indication. Flurbiprofen (Ocufen) and suprofen (Profenal) ...
Med Lett Drugs Ther. 1993 Sep 17;35(905):88-9 |  Show IntroductionHide Introduction

An ACE inhibitor after a Myocardial Infarction

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 1994  (Issue 928)
, based on Average Wholesale Price listings in First DataBank Price Alert, July 15, 1994 CONCLUSION ...
The US Food and Drug Administration has approved use of the angiotensin-converting enzyme (ACE) inhibitor captopril (Capoten) for patients with left ventricular dysfunction after a myocardial infarction. ACE inhibitors, widely used for treatment of hypertension, in recent years have also been used for treatment of heart failure (Medical Letter, 35:40, 1993).
Med Lett Drugs Ther. 1994 Aug 5;36(928):69-70 |  Show IntroductionHide Introduction

Valacyclovir

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 1996  (Issue 965)
be at least as effective in decreasing the duration of pain from herpes zoster. Preliminary data suggest ...
Valacyclovir (Valtrex - Glaxo Wellcome), an L- valyl ester of acyclovir (Zovirax), has been approved by the US Food and Drug Administration (FDA) for oral treatment of herpes zoster (shingles) in immunocompetent adults. Famciclovir (Famvir - Medical Letter, 36:97, 1994) is also available for this indication.
Med Lett Drugs Ther. 1996 Jan 5;38(965):3-4 |  Show IntroductionHide Introduction

Clarithromycin and Omeprazole for Helicobacter Pylori

   
The Medical Letter on Drugs and Therapeutics • Jun 07, 1996  (Issue 976)
have been published; most of the available data are based on use of a single regimen with bacteriological follow-up ...
The US Food and Drug Administration (FDA) recently approved the marketing of clarithromycin (Biaxin - Abbott), a macrolide antibiotic, and omeprazole (Prilosec - Astra Merck), a proton pump inhibitor, for concurrent use in treatment of duodenal ulcers associated with Helicobacter pylori.
Med Lett Drugs Ther. 1996 Jun 7;38(976):51-2 |  Show IntroductionHide Introduction